Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
New Insights in Gastric, Colorectal, and Pancreatic Cancer
share announcement

New Insights in Gastric, Colorectal, and Pancreatic Cancer

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 416

Special Issue Editor

Dr. John K. Triantafillidis

E-Mail Website
Guest Editor
Director IBD Unit, Metropolitan General Hospital, 15562 Holargos, Greece
Interests: nutrition; inflammatory bowel disease; malabsorption syndromes; chronic diarrhea; small and large bowel disorders; cancer epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastric, colorectal and pancreatic cancer represent the most important malignant neoplasms of the digestive system in terms of frequency and clinical importance. Despite the apparent changes regarding their frequency, it seems that these neoplasms are appearing at younger ages. Over the last years, significant progress has been made in the etiology, diagnosis and therapeutic treatment (surgical and conservative) of these three malignant neoplasms, including their pre-cancerous conditions (polyps, IBD, etc.). Advances in conservative treatment are especially impressive. For example, immunotherapy of these cancers alone or in combination with systemic chemotherapy is the therapeutic strategy of the present and the future.

This Special Issue focuses on the recent data regarding these three neoplasms, intending to cover among others, the following topics:

  • Mechanisms of carcinogenesis;
  • Tumor cell biology;
  • Hereditary gastric, CRC and pancreatic cancer;
  • Polyps (gastric and colorectal);
  • Biomarkers (diagnostic and prognostic);
  • Tumor staging;
  • Imaging techniques;
  • Animal models;
  • Stem cells;
  • Advances in chemotherapy;
  • Immunotherapy in gastric and pancreatic cancer, alone or in combination;
  • Advances in the treatment of metastatic pancreatic, CRC and gastric cancer.

We aspire for this Special Issue to cover at least part of the wide spectrum of the etiologies, diagnoses and treatments of these neoplasms, always in the light of a multidisciplinary approach.

Dr. John K. Triantafillidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer 
  • colorectal cancer 
  • pancreatic cancer
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 3331 KiB  
Article
Utility of Radiological Follow Up of Main-Duct Intraductal Papillary Mucinous Neoplasms and Mixed-Type Intraductal Papillary Mucinous Neoplasms
by Roie Tzadok, Rivka Kessner, Einat Ritter, Asaf Aizic, Hila Yashar, Sapir Lazar, Yuval Katz, Zur Ronen-Amsalem, Arthur Chernomorets, Oren Shibolet and Dana Ben-Ami Shor
Biomedicines 2024, 12(7), 1437; https://doi.org/10.3390/biomedicines12071437 - 27 Jun 2024
Viewed by 204
Abstract
Background: Intraductal papillary mucinous neoplasms (IPMNs) have the potential to evolve into pancreatic adenocarcinoma (PDAC). While main-duct IPMNs (MD-IPMNs), involving the main pancreatic duct (MPD), are less common than side-branch IPMNs (SB-IPMNs) or mixed-type IPMNs (mixed-IPMNs), their malignant transformation potential is far greater. [...] Read more.
Background: Intraductal papillary mucinous neoplasms (IPMNs) have the potential to evolve into pancreatic adenocarcinoma (PDAC). While main-duct IPMNs (MD-IPMNs), involving the main pancreatic duct (MPD), are less common than side-branch IPMNs (SB-IPMNs) or mixed-type IPMNs (mixed-IPMNs), their malignant transformation potential is far greater. Controversy exists between different guidelines in terms of recommended management strategies. This study was aimed at assessing the utility of the radiological follow up of MD-IPMNs and mixed-type IPMNs, including prevalence of worrisome radiological findings as well as clinical and laboratory parameters, and their correlation with the development of progression or pancreatic adenocarcinoma. Methods: Eighty-four patients with MD-IPMNs or mixed-type IPMNs who underwent at least one magnetic resonance cholangiopancreatography (MRCP) were included. Clinical and laboratory data were obtained retrospectively. A cross-sectional analysis was carried out to establish clinical and laboratory parameters associated with development of PDAC. A retrospective cohort analysis was performed on 44 patients who had at least six months of follow up, trying to identify factors correlating with worrisome radiological features. Results: Nine cases (10.7%) of PDAC were recorded in this cohort. The laboratory and imaging factors associated with cyst size progression greater than 5 mm during follow up were elevated alanine transaminase (ALT) levels, the maximal cyst size, and the MPD diameter. Cross-sectional analysis indicated that PDAC was associated with nausea (p = 0.01), as well as increased levels of aspartate aminotransferase (AST) (p = 0.05), gamma glutamyl transpeptidase (GGT) (p = 0.01), and alkaline phosphatase (ALP) (p = 0.01). Conclusions: Elevated levels of liver enzymes were associated with IPMN progression and, subsequently, the development of PDAC. ALT levels, maximal cyst size, and MPD diameter are associated with the progression of cyst size. These data may aid in risk-stratifying patients when determining the follow up approach for IPMNs. Full article
(This article belongs to the Special Issue New Insights in Gastric, Colorectal, and Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop